Use of antibiotics during pregnancy

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Objective: To describe the occurrence and distribution of antibiotic treatments, in addition their indications in control pregnant women in the population-based large dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Results: Of 38 151 control pregnant women who delivered later newborn infants without congenital abnormality, 6554 (17.2%) were treated by antibiotics. Most women (14.5%) had penicillin, while 1.2% and 0.7% of pregnant women were treated by cephalosporins and tetracyclines, respectively. More than 100 pregnant women used the following antibiotics: ampicillin (6.9%), penamecillin (5.9%), cefalexin (1.0%), phenoxymethylpenicillin (0.6%), oxytetracycline (0.5%), erythromycin (0.45%), benzylpenicillin-procain (0.4%) and benzylpenicillin+benzylpenicillin-procain (0.3%). Different antibiotics had different indications for treatment. The mean birth weight was significantly lower in the treated group compared to the untreated group. Practical implications: Different antibiotics have different chemical structures and indications for treatment. Therefore it is not appropriate to evaluate their teratogenic potential of combined antibiotic groups. There may be many interactions between underlying maternal diseases, other drug uses, further confounding factors and antibiotics studied, thus adequate controls are needed to estimate the adjusted teratogenic odds-risk ratios. European countries have different spectrum of antibiotic use. It would be necessary to know these baseline data of different populations. The anxiety and fear created by the notion that nearly all drugs cause congenital abnormalities may be more harmful than some proven human teratogenic drugs themselves. Thus a better risk-benefit estimation for antibiotic uses during pregnancy is an urgent and important task. Copyright (C) 1998 Elsevier Science Ireland Ltd.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalEuropean Journal of Obstetrics Gynecology and Reproductive Biology
Volume81
Issue number1
DOIs
Publication statusPublished - Oct 1 1998

Fingerprint

Anti-Bacterial Agents
Pregnancy
Penicillin G
Pregnant Women
Odds Ratio
Pharmaceutical Preparations
Penicillin V
Cephalexin
Tetracyclines
Oxytetracycline
Erythromycin
Cephalosporins
Ampicillin
Birth Weight
Penicillins
Population
Fear
Therapeutics
Anxiety
Mothers

Keywords

  • Antibiotic use during pregnancy
  • Higher birth weight
  • Risk-benefit estimation
  • Underlying maternal disorders

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Use of antibiotics during pregnancy. / Czeizel, E.; Rockenbauer, M.; Olsen, Jorn.

In: European Journal of Obstetrics Gynecology and Reproductive Biology, Vol. 81, No. 1, 01.10.1998, p. 1-8.

Research output: Contribution to journalArticle

@article{bd40671d9f3b46ea887028494e7b3daa,
title = "Use of antibiotics during pregnancy",
abstract = "Objective: To describe the occurrence and distribution of antibiotic treatments, in addition their indications in control pregnant women in the population-based large dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Results: Of 38 151 control pregnant women who delivered later newborn infants without congenital abnormality, 6554 (17.2{\%}) were treated by antibiotics. Most women (14.5{\%}) had penicillin, while 1.2{\%} and 0.7{\%} of pregnant women were treated by cephalosporins and tetracyclines, respectively. More than 100 pregnant women used the following antibiotics: ampicillin (6.9{\%}), penamecillin (5.9{\%}), cefalexin (1.0{\%}), phenoxymethylpenicillin (0.6{\%}), oxytetracycline (0.5{\%}), erythromycin (0.45{\%}), benzylpenicillin-procain (0.4{\%}) and benzylpenicillin+benzylpenicillin-procain (0.3{\%}). Different antibiotics had different indications for treatment. The mean birth weight was significantly lower in the treated group compared to the untreated group. Practical implications: Different antibiotics have different chemical structures and indications for treatment. Therefore it is not appropriate to evaluate their teratogenic potential of combined antibiotic groups. There may be many interactions between underlying maternal diseases, other drug uses, further confounding factors and antibiotics studied, thus adequate controls are needed to estimate the adjusted teratogenic odds-risk ratios. European countries have different spectrum of antibiotic use. It would be necessary to know these baseline data of different populations. The anxiety and fear created by the notion that nearly all drugs cause congenital abnormalities may be more harmful than some proven human teratogenic drugs themselves. Thus a better risk-benefit estimation for antibiotic uses during pregnancy is an urgent and important task. Copyright (C) 1998 Elsevier Science Ireland Ltd.",
keywords = "Antibiotic use during pregnancy, Higher birth weight, Risk-benefit estimation, Underlying maternal disorders",
author = "E. Czeizel and M. Rockenbauer and Jorn Olsen",
year = "1998",
month = "10",
day = "1",
doi = "10.1016/S0301-2115(98)00138-9",
language = "English",
volume = "81",
pages = "1--8",
journal = "European Journal of Obstetrics and Gynecology and Reproductive Biology",
issn = "0028-2243",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Use of antibiotics during pregnancy

AU - Czeizel, E.

AU - Rockenbauer, M.

AU - Olsen, Jorn

PY - 1998/10/1

Y1 - 1998/10/1

N2 - Objective: To describe the occurrence and distribution of antibiotic treatments, in addition their indications in control pregnant women in the population-based large dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Results: Of 38 151 control pregnant women who delivered later newborn infants without congenital abnormality, 6554 (17.2%) were treated by antibiotics. Most women (14.5%) had penicillin, while 1.2% and 0.7% of pregnant women were treated by cephalosporins and tetracyclines, respectively. More than 100 pregnant women used the following antibiotics: ampicillin (6.9%), penamecillin (5.9%), cefalexin (1.0%), phenoxymethylpenicillin (0.6%), oxytetracycline (0.5%), erythromycin (0.45%), benzylpenicillin-procain (0.4%) and benzylpenicillin+benzylpenicillin-procain (0.3%). Different antibiotics had different indications for treatment. The mean birth weight was significantly lower in the treated group compared to the untreated group. Practical implications: Different antibiotics have different chemical structures and indications for treatment. Therefore it is not appropriate to evaluate their teratogenic potential of combined antibiotic groups. There may be many interactions between underlying maternal diseases, other drug uses, further confounding factors and antibiotics studied, thus adequate controls are needed to estimate the adjusted teratogenic odds-risk ratios. European countries have different spectrum of antibiotic use. It would be necessary to know these baseline data of different populations. The anxiety and fear created by the notion that nearly all drugs cause congenital abnormalities may be more harmful than some proven human teratogenic drugs themselves. Thus a better risk-benefit estimation for antibiotic uses during pregnancy is an urgent and important task. Copyright (C) 1998 Elsevier Science Ireland Ltd.

AB - Objective: To describe the occurrence and distribution of antibiotic treatments, in addition their indications in control pregnant women in the population-based large dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Results: Of 38 151 control pregnant women who delivered later newborn infants without congenital abnormality, 6554 (17.2%) were treated by antibiotics. Most women (14.5%) had penicillin, while 1.2% and 0.7% of pregnant women were treated by cephalosporins and tetracyclines, respectively. More than 100 pregnant women used the following antibiotics: ampicillin (6.9%), penamecillin (5.9%), cefalexin (1.0%), phenoxymethylpenicillin (0.6%), oxytetracycline (0.5%), erythromycin (0.45%), benzylpenicillin-procain (0.4%) and benzylpenicillin+benzylpenicillin-procain (0.3%). Different antibiotics had different indications for treatment. The mean birth weight was significantly lower in the treated group compared to the untreated group. Practical implications: Different antibiotics have different chemical structures and indications for treatment. Therefore it is not appropriate to evaluate their teratogenic potential of combined antibiotic groups. There may be many interactions between underlying maternal diseases, other drug uses, further confounding factors and antibiotics studied, thus adequate controls are needed to estimate the adjusted teratogenic odds-risk ratios. European countries have different spectrum of antibiotic use. It would be necessary to know these baseline data of different populations. The anxiety and fear created by the notion that nearly all drugs cause congenital abnormalities may be more harmful than some proven human teratogenic drugs themselves. Thus a better risk-benefit estimation for antibiotic uses during pregnancy is an urgent and important task. Copyright (C) 1998 Elsevier Science Ireland Ltd.

KW - Antibiotic use during pregnancy

KW - Higher birth weight

KW - Risk-benefit estimation

KW - Underlying maternal disorders

UR - http://www.scopus.com/inward/record.url?scp=0032189523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032189523&partnerID=8YFLogxK

U2 - 10.1016/S0301-2115(98)00138-9

DO - 10.1016/S0301-2115(98)00138-9

M3 - Article

C2 - 9846705

AN - SCOPUS:0032189523

VL - 81

SP - 1

EP - 8

JO - European Journal of Obstetrics and Gynecology and Reproductive Biology

JF - European Journal of Obstetrics and Gynecology and Reproductive Biology

SN - 0028-2243

IS - 1

ER -